CBM Biopharma

Dallas, United States Founded: 2018 • Age: 8 yrs Acquired By AIkido Pharma
Small molecule therapeutics for cancer treatment are developed.
Annual revenue - Latest available
Total funding - Funding intelligence
Employees - Tracked headcount
Investors 1 Known backers
Products - Services tracked
Competitors 10 Brand Intelligence

About CBM Biopharma

CBM Biopharma is a company based in Dallas (United States) founded in 2018 was acquired by AIkido Pharma in June 2019. CBM Biopharma operates in a competitive market with competitors including Jazz Pharmaceuticals, BridgeBio, Spark Therapeutics, Alnylam and ATAI, among others.

  • Headquarter Dallas, United States
  • Sectors
    Healthcare
  • Phone
    Locked
  • Website
    Locked
Operational Areas
Healthcare → Biotechnology, Genomics & Life Sciences Research Unlock Sub-Sector Unlock Segment
Healthcare → Healthcare Products & Supplies Unlock Sub-Sector Unlock Segment
Key Metrics
  • Annual Revenue
    Not available
  • Net Profit
    Not available
  • EBITDA
    Not available
  • Latest Funding Round
    Not available
  • Investors
  • Employee Count
    Not available
  • Acquired by
    AIkido Pharma

    (Jun 19, 2019)

Upgrade to premium

Unlock complete access to The Company Check

Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.

Upgrade to Premium No viewing limits. Your plan controls exports and screening usage.
Included in your Premium account
  • Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
  • Full access to every database India & global coverage, advanced filters and rich profile details
  • Always-on access from your team account Single premium plan for everything you see on the portal

Funding Insights of CBM Biopharma

Premium access

Detailed funding history for CBM Biopharma

Round names, dates, amounts, investors, and valuation history require an active premium plan.

  • Round names and dates
  • Funding amounts
  • Participating investors
  • Valuation history

Verified entity values are shown only after access is granted.

Investors in CBM Biopharma

CBM Biopharma has secured backing from 1 investor. Prominent investors backing the company include AIkido Pharma.

All
Investor Description Founded Year Domain Location
Drugs for treating pancreatic cancer and leukemia are developed.
Locked Locked Locked
Premium access

Investor details for CBM Biopharma

Investor domains, locations, round participation, and complete history require an active premium plan.

  • Investor domains
  • Investor locations
  • Funding rounds
  • Participation history

Verified entity values are shown only after access is granted.

Investments & Acquisitions by CBM Biopharma

Investments
Premium access

Investment portfolio details for CBM Biopharma

Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.

  • Portfolio identities
  • Transaction dates
  • Round details
  • Investment values

Verified entity values are shown only after access is granted.

Financial Statements - CBM Biopharma

Premium access

Detailed financials for CBM Biopharma

Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.

  • Historical revenue
  • Profit trends
  • Statement rows
  • Financial ratios

Verified entity values are shown only after access is granted.

Cbm Biopharma Comparisons

CBM Biopharma Primary company
Description
Small molecule therapeutics for cancer treatment are develop...
Location
Dallas, United States
Founded Year
2018
Annual Revenue
Not available
Net Profit
Not available
EBITDA
Not available
Employees
Not available
Premium access

Peer comparison for CBM Biopharma

Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.

  • Named peers
  • Headcount comparison
  • Funding comparison
  • Operating benchmarks

Verified entity values are shown only after access is granted.

+
Add Comparison
Available on Premium

Competitors of CBM Biopharma

CBM Biopharma operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Jazz Pharmaceuticals, BridgeBio, Spark Therapeutics, Alnylam and ATAI, among others.

Company Name Domain Founded year HQ Location Description
Locked Locked Locked
Novel biopharmaceutical medicines are developed for unmet medical needs.
Locked Locked Locked
Therapeutics for genetic diseases are developed through targeted interventions.
Locked Locked Locked
Gene therapies for rare diseases including retinal dystrophies are developed.
Locked Locked Locked
RNA interference-based therapeutics are developed for multiple disorders.
Locked Locked Locked
A biopharmaceutical company accelerating innovative mental health treatments.
Locked Locked Locked
An AI-enabled platform is developed for infectious disease treatment.
Premium access

Detailed competitors of CBM Biopharma

Competitor domains, locations, full profiles, and operating metrics require an active premium plan.

  • Domains and locations
  • Full company profiles
  • Operating metrics
  • Competitive positioning

Verified entity values are shown only after access is granted.

Latest news on Cbm Biopharma

Premium access

Complete news archive for CBM Biopharma

Full article history, source details, and older brand coverage require an active premium plan.

  • Full article archive
  • Source and publication date
  • Older coverage
  • Brand-specific news history

Verified entity values are shown only after access is granted.

Frequently Asked Questions about CBM Biopharma

CBM Biopharma was founded in 2018.

CBM Biopharma is headquartered in Dallas, United States. It is registered at Dallas, Texas, United States.

CBM Biopharma was founded in 2018 in Dallas, United States, and operates in the biopharmaceutical sector focused on oncology. Small molecule-based therapeutics are developed to address cancer challenges. The drug candidate KPC34 is designed by combining a DNA damaging agent with targeted therapy to counter resistance mechanisms, targeting acute myeloid leukemia (AML) and acute lymphoblastic leukemia (ALL). DHA-dFdC has also been developed for pancreatic cancer treatment.

CBM Biopharma's top competitors include Jazz Pharmaceuticals, Spark Therapeutics and BridgeBio.

CBM Biopharma has 1 investor. Key investors include AIkido Pharma.

Explore millions of companies — effortlessly

Access structured, verified intelligence on 7M+ companies across industries, sectors, and global markets. From early-stage startups to large enterprises, discover ownership, leadership, funding, financials, acquisitions, and market signals — all in one powerful platform.

Free account with essential features Instant access to company reports Enterprise solutions available